Nanostructured porous Si-based nanoparticles for targeted drug delivery

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69 - 90; http://dx.doi.org/10.3322/caac.20107; PMID: 21296855
   PubMed Web of Science ®Google Scholar
• Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol 2012; 23:1044 - 52; http://dx.doi.org/10.1093/annonc/mds024; PMID: 22373539
   PubMed Web of Science ®Google Scholar
• Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2:750 - 63; http://dx.doi.org/10.1038/nrc903; PMID: 12360278
   PubMed Web of Science ®Google Scholar
• Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010; 31:358 - 65; http://dx.doi.org/10.1016/j.biomaterials.2009.09.048; PMID: 19800114
   PubMed Web of Science ®Google Scholar
• Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today 2010; 15:842 - 50; http://dx.doi.org/10.1016/j.drudis.2010.08.006; PMID: 20727417
   PubMed Web of Science ®Google Scholar
• Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin 2008; 58:97 - 110; http://dx.doi.org/10.3322/CA.2007.0003; PMID: 18227410
   PubMed Web of Science ®Google Scholar
• Manasmita D, Debasish M, Maiti T, Basak A, Pramanik P. Bio-functionalization of magnetite nanoparticles using an aminophosphonic acid coupling agent: new, ultradispersed, iron-oxide folate nanoconjugates for cancer-specific targeting. Nanotech 2008; 19:415101; http://dx.doi.org/10.1088/0957-4484/19/41/415101
   PubMed Web of Science ®Google Scholar
• Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005; 5:161 - 71; http://dx.doi.org/10.1038/nrc1566; PMID: 15738981
   PubMed Web of Science ®Google Scholar
• Hamidi M, Shahbazi MA, Rostamizadeh K. Copolymers: efficient carriers for intelligent nanoparticulate drug targeting and gene therapy. Macromol Biosci 2012; 12:144 - 64; http://dx.doi.org/10.1002/mabi.201100193; PMID: 22006795
   PubMed Web of Science ®Google Scholar
• Chou LY, Ming K, Chan WC. Strategies for the intracellular delivery of nanoparticles. Chem Soc Rev 2011; 40:233 - 45; http://dx.doi.org/10.1039/c0cs00003e; PMID: 20886124
   PubMed Web of Science ®Google Scholar
• von Maltzahn G, Park JH, Lin KY, Singh N, Schwöppe C, Mesters R, et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater 2011; 10:545 - 52; http://dx.doi.org/10.1038/nmat3049; PMID: 21685903
   PubMed Web of Science ®Google Scholar
• Park JH, von Maltzahn G, Xu MJ, Fogal V, Kotamraju VR, Ruoslahti E, et al. Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc Natl Acad Sci U S A 2010; 107:981 - 6; http://dx.doi.org/10.1073/pnas.0909565107; PMID: 20080556
   PubMed Web of Science ®Google Scholar
• Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, O’Neil CP, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007; 25:1159 - 64; http://dx.doi.org/10.1038/nbt1332; PMID: 17873867
   PubMed Web of Science ®Google Scholar
• Vallet-Regí M. Nanostructured mesoporous silica matrices in nanomedicine. J Intern Med 2010; 267:22 - 43; http://dx.doi.org/10.1111/j.1365-2796.2009.02190.x; PMID: 20059642
   PubMed Web of Science ®Google Scholar
• Vallet-Regí M, Balas F, Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Ed Engl 2007; 46:7548 - 58; http://dx.doi.org/10.1002/anie.200604488; PMID: 17854012
   PubMed Web of Science ®Google Scholar
• Vivero-Escoto JL, Slowing II, Trewyn BG, Lin VS. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small 2010; 6:1952 - 67; http://dx.doi.org/10.1002/smll.200901789; PMID: 20690133
   PubMed Web of Science ®Google Scholar
• Santos HA, Bimbo LM, Lehto VP, Airaksinen AJ, Salonen J, Hirvonen J. Multifunctional porous silicon for therapeutic drug delivery and imaging. Curr Drug Discov Technol 2011; 8:228 - 49; http://dx.doi.org/10.2174/157016311796799053; PMID: 21291407
   PubMedGoogle Scholar
• Salonen J, Kaukonen AM, Hirvonen J, Lehto VP. Mesoporous silicon in drug delivery applications. J Pharm Sci 2008; 97:632 - 53; http://dx.doi.org/10.1002/jps.20999; PMID: 17546667
   PubMed Web of Science ®Google Scholar
• Godin B, Tasciotti E, Liu X, Serda RE, Ferrari M. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res 2011; 44:979 - 89; http://dx.doi.org/10.1021/ar200077p; PMID: 21902173
   PubMed Web of Science ®Google Scholar
• Li Z, Barnes JC, Bosoy A, Stoddart JF, Zink JI. Mesoporous silica nanoparticles in biomedical applications. Chem Soc Rev 2012; 41:2590 - 605; http://dx.doi.org/10.1039/c1cs15246g; PMID: 22216418
   PubMed Web of Science ®Google Scholar
• Hudson SP, Padera RF, Langer R, Kohane DS. The biocompatibility of mesoporous silicates. Biomaterials 2008; 29:4045 - 55; http://dx.doi.org/10.1016/j.biomaterials.2008.07.007; PMID: 18675454
   PubMed Web of Science ®Google Scholar
• Kunzmann A, Andersson B, Thurnherr T, Krug H, Scheynius A, Fadeel B. Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. Biochim Biophys Acta 2011; 1810:361 - 73; http://dx.doi.org/10.1016/j.bbagen.2010.04.007; PMID: 20435096
   PubMed Web of Science ®Google Scholar
• Bimbo LM, Peltonen L, Hirvonen J, Santos HA. Toxicological Profile of Therapeutic Nanodelivery Systems. Curr Drug Metab 2012; 13:1068 - 86; PMID: 22380014
   PubMed Web of Science ®Google Scholar
• Rosenholm JM, Sahlgren C, Lindén M. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles--opportunities & challenges. Nanoscale 2010; 2:1870 - 83; http://dx.doi.org/10.1039/c0nr00156b; PMID: 20730166
   PubMed Web of Science ®Google Scholar
• Rosenholm JM, Sahlgren C, Lindén M. Multifunctional mesoporous silica nanoparticles for combined therapeutic, diagnostic and targeted action in cancer treatment. Curr Drug Targets 2011; 12:1166 - 86; http://dx.doi.org/10.2174/138945011795906624; PMID: 21443474
   PubMed Web of Science ®Google Scholar
• Rosenholm JM, Mamaeva V, Sahlgren C, Lindén M. Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage. Nanomedicine (Lond) 2012; 7:111 - 20; http://dx.doi.org/10.2217/nnm.11.166; PMID: 22191780
   PubMed Web of Science ®Google Scholar
• Jaganathan H, Godin B. Biocompatibility assessment of Si-based nano- and micro-particles. Adv Drug Deliv Rev 2012; In press http://dx.doi.org/10.1016/j.addr.2012.05.008; PMID: 22634160
   PubMed Web of Science ®Google Scholar
• Salonen J, Lehto V-P. Fabrication and chemical surface modification of mesoporous silicon for biomedical applications. Chem Eng J 2008; 137:162 - 72; http://dx.doi.org/10.1016/j.cej.2007.09.001
   Web of Science ®Google Scholar
• Zhang J, Li X, Rosenholm JM, Gu HC. Synthesis and characterization of pore size-tunable magnetic mesoporous silica nanoparticles. J Colloid Interface Sci 2011; 361:16 - 24; http://dx.doi.org/10.1016/j.jcis.2011.05.038; PMID: 21689824
   PubMed Web of Science ®Google Scholar
• Tang F, Li L, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater 2012; 24:1504 - 34; http://dx.doi.org/10.1002/adma.201104763; PMID: 22378538
   PubMed Web of Science ®Google Scholar
• Betty CA. Porous silicon: a resourceful material for nanotechnology. Recent Pat Nanotechnol 2008; 2:128 - 36; http://dx.doi.org/10.2174/187221008784534514; PMID: 19076047
   PubMedGoogle Scholar
• Anglin EJ, Cheng L, Freeman WR, Sailor MJ. Porous silicon in drug delivery devices and materials. Adv Drug Deliv Rev 2008; 60:1266 - 77; http://dx.doi.org/10.1016/j.addr.2008.03.017; PMID: 18508154
   PubMed Web of Science ®Google Scholar
• Mamaeva V, Rosenholm JM, Bate-Eya LT, Bergman L, Peuhu E, Duchanoy A, et al. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Mol Ther 2011; 19:1538 - 46; http://dx.doi.org/10.1038/mt.2011.105; PMID: 21629222
   PubMed Web of Science ®Google Scholar
• Kinnari P, Mäkilä E, Heikkilä T, Salonen J, Hirvonen J, Santos HA. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. Int J Pharm 2011; 414:148 - 56; http://dx.doi.org/10.1016/j.ijpharm.2011.05.021; PMID: 21601623
   PubMed Web of Science ®Google Scholar
• Santos HA, Salonen J, Bimbo LM, Lehto VP, Peltonen L, Hirvonen J. Mesoporous materials as controlled drug delivery formulations. J Drug Deliv Sci Tech 2011; 21:139 - 55
   Web of Science ®Google Scholar
• Bimbo LM, Mäkilä E, Laaksonen T, Lehto VP, Salonen J, Hirvonen J, et al. Drug permeation across intestinal epithelial cells using porous silicon nanoparticles. Biomaterials 2011; 32:2625 - 33; http://dx.doi.org/10.1016/j.biomaterials.2010.12.011; PMID: 21194747
   PubMed Web of Science ®Google Scholar
• Bimbo LM, Mäkilä E, Raula J, Laaksonen T, Laaksonen P, Strommer K, et al. Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles. Biomaterials 2011; 32:9089 - 99; http://dx.doi.org/10.1016/j.biomaterials.2011.08.011; PMID: 21864895
   PubMed Web of Science ®Google Scholar
• Bimbo LM, Sarparanta M, Santos HA, Airaksinen AJ, Mäkilä E, Laaksonen T, et al. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. ACS Nano 2010; 4:3023 - 32; http://dx.doi.org/10.1021/nn901657w; PMID: 20509673
   PubMed Web of Science ®Google Scholar
• Sarparanta M, Mäkilä E, Heikkilä T, Salonen J, Kukk E, Lehto VP, et al. ¹⁸F-labeled modified porous silicon particles for investigation of drug delivery carrier distribution in vivo with positron emission tomography. Mol Pharm 2011; 8:1799 - 806; http://dx.doi.org/10.1021/mp2001654; PMID: 21875120
   PubMed Web of Science ®Google Scholar
• Sarparanta MP, Bimbo LM, Mäkilä EM, Salonen JJ, Laaksonen PH, Helariutta AM, et al. The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems. Biomaterials 2012; 33:3353 - 62; http://dx.doi.org/10.1016/j.biomaterials.2012.01.029; PMID: 22285465
   PubMed Web of Science ®Google Scholar
• Bimbo LM, Sarparanta M, Mäkilä E, Laaksonen T, Laaksonen P, Salonen J, et al. Cellular interactions of surface modified nanoporous silicon particles. Nanoscale 2012; 4:3184 - 92; http://dx.doi.org/10.1039/c2nr30397c; PMID: 22508528
   PubMed Web of Science ®Google Scholar
• Limnell T, Santos HA, Mäkilä E, Heikkilä T, Salonen J, Murzin DY, et al. Drug delivery formulations of ordered and nonordered mesoporous silica: comparison of three drug loading methods. J Pharm Sci 2011; 100:3294 - 306; http://dx.doi.org/10.1002/jps.22577; PMID: 21520084
   PubMed Web of Science ®Google Scholar
• Limnell T, Heikkilä T, Santos HA, Sistonen S, Hellstén S, Laaksonen T, et al. Physicochemical stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15 microparticles. Int J Pharm 2011; 416:242 - 51; PMID: 21763766
   PubMed Web of Science ®Google Scholar
• Tang H, Guo J, Sun Y, Chang B, Ren Q, Yang W. Facile synthesis of pH sensitive polymer-coated mesoporous silica nanoparticles and their application in drug delivery. Int J Pharm 2011; 421:388 - 96; http://dx.doi.org/10.1016/j.ijpharm.2011.10.013; PMID: 22001840
   PubMed Web of Science ®Google Scholar
• Slowing I, Trewyn BG, Lin VS. Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells. J Am Chem Soc 2006; 128:14792 - 3; http://dx.doi.org/10.1021/ja0645943; PMID: 17105274
   PubMed Web of Science ®Google Scholar
• Lu J, Liong M, Sherman S, Xia T, Kovochich M, Nel AE, et al. Mesoporous silica nanoparticles for cancer therapy: energy-dependent cellular uptake and delivery of paclitaxel to cancer cells. Nanobiotechnology 2007; 3:89 - 95; http://dx.doi.org/10.1007/s12030-008-9003-3; PMID: 19936038
   PubMedGoogle Scholar
• Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 2010; 6:1794 - 805; http://dx.doi.org/10.1002/smll.201000538; PMID: 20623530
   PubMed Web of Science ®Google Scholar
• Gu L, Park JH, Duong KH, Ruoslahti E, Sailor MJ. Magnetic luminescent porous silicon microparticles for localized delivery of molecular drug payloads. Small 2010; 6:2546 - 52; http://dx.doi.org/10.1002/smll.201000841; PMID: 20814923
   PubMed Web of Science ®Google Scholar
• Wu J, Sailor MJ. Chitosan hydrogel-capped porous SiO2 as a pH responsive nano-valve for triggered release of insulin. Adv Funct Mater 2009; 19:733 - 41; http://dx.doi.org/10.1002/adfm.200800921
   Web of Science ®Google Scholar
• Yang X, Liu X, Liu Z, Pu F, Ren J, Qu X. Near-infrared light-triggered, targeted drug delivery to cancer cells by aptamer gated nanovehicles. Adv Mater 2012; 24:2890 - 5; http://dx.doi.org/10.1002/adma.201104797; PMID: 22539076
   PubMed Web of Science ®Google Scholar
• Wang LS, Wu LC, Lu SY, Chang LL, Teng IT, Yang CM, et al. Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: improved water suspensibility and decreased nonspecific protein binding. ACS Nano 2010; 4:4371 - 9; http://dx.doi.org/10.1021/nn901376h; PMID: 20731423
   PubMed Web of Science ®Google Scholar
• Wu EC, Park JH, Park J, Segal E, Cunin F, Sailor MJ. Oxidation-triggered release of fluorescent molecules or drugs from mesoporous Si microparticles. ACS Nano 2008; 2:2401 - 9; http://dx.doi.org/10.1021/nn800592q; PMID: 19206408
   PubMed Web of Science ®Google Scholar
• Rosenholm JM, Meinander A, Peuhu E, Niemi R, Eriksson JE, Sahlgren C, et al. Targeting of porous hybrid silica nanoparticles to cancer cells. ACS Nano 2009; 3:197 - 206; http://dx.doi.org/10.1021/nn800781r; PMID: 19206267
   PubMed Web of Science ®Google Scholar
• Slowing II, Vivero-Escoto JL, Wu CW, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 2008; 60:1278 - 88; http://dx.doi.org/10.1016/j.addr.2008.03.012; PMID: 18514969
   PubMed Web of Science ®Google Scholar
• Park C, Oh K, Lee SC, Kim C. Controlled release of guest molecules from mesoporous silica particles based on a pH-responsive polypseudorotaxane motif. Angew Chem Int Ed Engl 2007; 46:1455 - 7; http://dx.doi.org/10.1002/anie.200603404; PMID: 17221893
   PubMed Web of Science ®Google Scholar
• Luo Z, Cai K, Hu Y, Zhao L, Liu P, Duan L, et al. Mesoporous silica nanoparticles end-capped with collagen: redox-responsive nanoreservoirs for targeted drug delivery. Angew Chem Int Ed Engl 2011; 50:640 - 3; http://dx.doi.org/10.1002/anie.201005061; PMID: 21226142
   PubMed Web of Science ®Google Scholar
• Schlossbauer A, Kecht J, Bein T. Biotin-avidin as a protease-responsive cap system for controlled guest release from colloidal mesoporous silica. Angew Chem Int Ed Engl 2009; 48:3092 - 5; http://dx.doi.org/10.1002/anie.200805818; PMID: 19309022
   PubMed Web of Science ®Google Scholar
• Murakami K, Yu X, Watanabe S, Kato T, Inoue Y, Sugawara K. Synthesis of thermosensitive polymer/mesoporous silica composite and its temperature dependence of anion exchange property. J Colloid Interface Sci 2011; 354:771 - 6; http://dx.doi.org/10.1016/j.jcis.2010.10.040; PMID: 21056426
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu H, Li F, Ruan Q, Wang H, Fujiwara M, et al. Dipolar molecules as impellers achieving electric-field-stimulated release. J Am Chem Soc 2010; 132:1450 - 1; http://dx.doi.org/10.1021/ja907560y; PMID: 20078044
   PubMed Web of Science ®Google Scholar
• Hu SH, Liu TY, Huang HY, Liu DM, Chen SY. Magnetic-sensitive silica nanospheres for controlled drug release. Langmuir 2008; 24:239 - 44; http://dx.doi.org/10.1021/la701570z; PMID: 18052081
   PubMed Web of Science ®Google Scholar
• Zhu Y, Meng W, Hanagata N. Cytosine-phosphodiester-guanine oligodeoxynucleotide (CpG ODN)-capped hollow mesoporous silica particles for enzyme-triggered drug delivery. Dalton Trans 2011; 40:10203 - 8; http://dx.doi.org/10.1039/c1dt11114k; PMID: 21901222
   PubMed Web of Science ®Google Scholar
• Andrew JS, Anglin EJ, Wu EC, Chen MY, Cheng L, Freeman WR, et al. Sustained Release of a Monoclonal Antibody from Electrochemically Prepared Mesoporous Silicon Oxide. Adv Funct Mater 2010; 20:4168 - 74; http://dx.doi.org/10.1002/adfm.201000907; PMID: 21274422
   PubMed Web of Science ®Google Scholar
• Tanaka T, Decuzzi P, Cristofanilli M, Sakamoto JH, Tasciotti E, Robertson FM, et al. Nanotechnology for breast cancer therapy. Biomed Microdevices 2009; 11:49 - 63; http://dx.doi.org/10.1007/s10544-008-9209-0; PMID: 18663578
   PubMed Web of Science ®Google Scholar
• Scanlon KJ. Cancer gene therapy: challenges and opportunities. Anticancer Res 2004; 24:2A 501 - 4; PMID: 15152950
   PubMedGoogle Scholar
• Farrell D, Ptak K, Panaro NJ, Grodzinski P. Nanotechnology-based cancer therapeutics--promise and challenge--lessons learned through the NCI Alliance for Nanotechnology in Cancer. Pharm Res 2011; 28:273 - 8; http://dx.doi.org/10.1007/s11095-010-0214-7; PMID: 20814720
   PubMed Web of Science ®Google Scholar
• Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 2010; 624:25 - 37; http://dx.doi.org/10.1007/978-1-60761-609-2_3; PMID: 20217587
   PubMedGoogle Scholar
• Lin YS, Haynes CL. Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity. J Am Chem Soc 2010; 132:4834 - 42; http://dx.doi.org/10.1021/ja910846q; PMID: 20230032
   PubMed Web of Science ®Google Scholar
• He Q, Zhang Z, Gao Y, Shi J, Li Y. Intracellular localization and cytotoxicity of spherical mesoporous silica nano- and microparticles. Small 2009; 5:2722 - 9; http://dx.doi.org/10.1002/smll.200900923; PMID: 19780070
   PubMed Web of Science ®Google Scholar
• Park JH, Gu L, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater 2009; 8:331 - 6; http://dx.doi.org/10.1038/nmat2398; PMID: 19234444
   PubMed Web of Science ®Google Scholar
• Wu SH, Lin YS, Hung Y, Chou YH, Hsu YH, Chang C, et al. Multifunctional mesoporous silica nanoparticles for intracellular labeling and animal magnetic resonance imaging studies. Chembiochem 2008; 9:53 - 7; http://dx.doi.org/10.1002/cbic.200700509; PMID: 17999392
   PubMed Web of Science ®Google Scholar
• Slowing II, Wu CW, Vivero-Escoto JL, Lin VS. Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells. Small 2009; 5:57 - 62; http://dx.doi.org/10.1002/smll.200800926; PMID: 19051185
   PubMed Web of Science ®Google Scholar
• Liu J, Stace-Naughton A, Jiang X, Brinker CJ. Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles. J Am Chem Soc 2009; 131:1354 - 5; http://dx.doi.org/10.1021/ja808018y; PMID: 19173660
   PubMed Web of Science ®Google Scholar
• Ashley CE, Carnes EC, Phillips GK, Padilla D, Durfee PN, Brown PA, et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater 2011; 10:389 - 97; http://dx.doi.org/10.1038/nmat2992; PMID: 21499315
   PubMed Web of Science ®Google Scholar
• He Q, Zhang J, Shi J, Zhu Z, Zhang L, Bu W, et al. The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses. Biomaterials 2010; 31:1085 - 92; http://dx.doi.org/10.1016/j.biomaterials.2009.10.046; PMID: 19880176
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hamad I. Liposome-mediated triggering of complement cascade. J Liposome Res 2008; 18:195 - 209; http://dx.doi.org/10.1080/08982100802309552; PMID: 18720195
   PubMed Web of Science ®Google Scholar
• He Q, Shi J, Chen F, Zhu M, Zhang L. An anticancer drug delivery system based on surfactant-templated mesoporous silica nanoparticles. Biomaterials 2010; 31:3335 - 46; http://dx.doi.org/10.1016/j.biomaterials.2010.01.015; PMID: 20106517
   PubMed Web of Science ®Google Scholar
• Huang X, Teng X, Chen D, Tang F, He J. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials 2010; 31:438 - 48; http://dx.doi.org/10.1016/j.biomaterials.2009.09.060; PMID: 19800115
   PubMed Web of Science ®Google Scholar
• Yu T, Malugin A, Ghandehari H. Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. ACS Nano 2011; 5:5717 - 28; http://dx.doi.org/10.1021/nn2013904; PMID: 21630682
   PubMed Web of Science ®Google Scholar
• Tao Z, Toms B, Goodisman J, Asefa T. Mesoporous silica microparticles enhance the cytotoxicity of anticancer platinum drugs. ACS Nano 2010; 4:789 - 94; http://dx.doi.org/10.1021/nn9015345; PMID: 20131868
   PubMed Web of Science ®Google Scholar
• Huang DM, Hung Y, Ko BS, Hsu SC, Chen WH, Chien CL, et al. Highly efficient cellular labeling of mesoporous nanoparticles in human mesenchymal stem cells: implication for stem cell tracking. FASEB J 2005; 19:2014 - 6; http://dx.doi.org/10.1096/fj.05-4288fje; PMID: 16230334
   PubMed Web of Science ®Google Scholar
• Lu F, Wu SH, Hung Y, Mou CY. Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles. Small 2009; 5:1408 - 13; http://dx.doi.org/10.1002/smll.200900005; PMID: 19296554
   PubMed Web of Science ®Google Scholar
• Tao Z, Toms BB, Goodisman J, Asefa T. Mesoporosity and functional group dependent endocytosis and cytotoxicity of silica nanomaterials. Chem Res Toxicol 2009; 22:1869 - 80; http://dx.doi.org/10.1021/tx900276u; PMID: 19817448
   PubMed Web of Science ®Google Scholar
• Popat A, Liu J, Hu Q, Kennedy M, Peters B, Lu GQ, et al. Adsorption and release of biocides with mesoporous silica nanoparticles. Nanoscale 2012; 4:970 - 5; http://dx.doi.org/10.1039/c2nr11691j; PMID: 22200056
   PubMed Web of Science ®Google Scholar
• Zhang H, Li Z, Xu P, Wu R, Wang L, Xiang Y, et al. Synthesis of novel mesoporous silica nanoparticles for loading and release of ibuprofen. J Control Release 2011; 152:Suppl 1 e38 - 9; http://dx.doi.org/10.1016/j.jconrel.2011.08.108; PMID: 22195911
   PubMedGoogle Scholar
• Kiekens F, Eelen S, Verheyden L, Daems T, Martens J, Van Den Mooter G. Use of ordered mesoporous silica to enhance the oral bioavailability of ezetimibe in dogs. J Pharm Sci 2012; 101:1136 - 44; http://dx.doi.org/10.1002/jps.23016; PMID: 22190350
   PubMed Web of Science ®Google Scholar
• Gan Q, Dai D, Yuan Y, Qian J, Sha S, Shi J, et al. Effect of size on the cellular endocytosis and controlled release of mesoporous silica nanoparticles for intracellular delivery. Biomed Microdevices 2012; 14:259 - 70; http://dx.doi.org/10.1007/s10544-011-9604-9; PMID: 22124885
   PubMed Web of Science ®Google Scholar
• Chung TH, Wu SH, Yao M, Lu CW, Lin YS, Hung Y, et al. The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials 2007; 28:2959 - 66; http://dx.doi.org/10.1016/j.biomaterials.2007.03.006; PMID: 17397919
   PubMed Web of Science ®Google Scholar
• Maxfield FR, McGraw TE. Endocytic recycling. Nat Rev Mol Cell Biol 2004; 5:121 - 32; http://dx.doi.org/10.1038/nrm1315; PMID: 15040445
   PubMed Web of Science ®Google Scholar
• He X, Nie H, Wang K, Tan W, Wu X, Zhang P. In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles. Anal Chem 2008; 80:9597 - 603; http://dx.doi.org/10.1021/ac801882g; PMID: 19007246
   PubMed Web of Science ®Google Scholar
• Taylor AE, Granger DN. Equivalent pore modeling: vesicles and channels. Fed Proc 1983; 42:2440 - 5; PMID: 6840295
   PubMedGoogle Scholar
• Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133:95 - 109; PMID: 2459969
   PubMed Web of Science ®Google Scholar
• Maeda H, Noguchi Y, Sato K, Akaike T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res 1994; 85:331 - 4; http://dx.doi.org/10.1111/j.1349-7006.1994.tb02362.x; PMID: 7515384
   PubMedGoogle Scholar
• Hon NK, Shaposhnik Z, Diebold ED, Tamanoi F, Jalali B. Tailoring the biodegradability of porous silicon nanoparticles. J Biomed Mater Res A 2012; In press http://dx.doi.org/10.1002/jbm.a.34294; PMID: 22767395
   PubMed Web of Science ®Google Scholar
• De Angelis F, Pujia A, Falcone C, Iaccino E, Palmieri C, Liberale C, et al. Water soluble nanoporous nanoparticle for in vivo targeted drug delivery and controlled release in B cells tumor context. Nanoscale 2010; 2:2230 - 6; http://dx.doi.org/10.1039/c0nr00161a; PMID: 20835434
   PubMed Web of Science ®Google Scholar
• Kim J, Kim HS, Lee N, Kim T, Kim H, Yu T, et al. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew Chem Int Ed Engl 2008; 47:8438 - 41; http://dx.doi.org/10.1002/anie.200802469; PMID: 18726979
   PubMed Web of Science ®Google Scholar
• Lee JE, Lee N, Kim H, Kim J, Choi SH, Kim JH, et al. Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. J Am Chem Soc 2010; 132:552 - 7; http://dx.doi.org/10.1021/ja905793q; PMID: 20017538
   PubMed Web of Science ®Google Scholar
• Lu J, Li Z, Zink JI, Tamanoi F. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine 2012; 8:212 - 20; http://dx.doi.org/10.1016/j.nano.2011.06.002; PMID: 21703996
   PubMed Web of Science ®Google Scholar
• Martin KR. The chemistry of silica and its potential health benefits. J Nutr Health Aging 2007; 11:94 - 7; PMID: 17435951
   PubMed Web of Science ®Google Scholar
• Steinbacher JL, Lathrop SA, Cheng K, Hillegass JM, Butnor KJ, Kauppinen RA, et al. Gd-labeled microparticles in MRI: in vivo imaging of microparticles after intraperitoneal injection. Small 2010; 6:2678 - 82; http://dx.doi.org/10.1002/smll.201001447; PMID: 21069757
   PubMed Web of Science ®Google Scholar
• Huang X, Li L, Liu T, Hao N, Liu H, Chen D, et al. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano 2011; 5:5390 - 9; http://dx.doi.org/10.1021/nn200365a; PMID: 21634407
   PubMed Web of Science ®Google Scholar
• Lee C-H, Cheng S-H, Wang Y-J, Chen Y-C, Chen N-T, Souris J, et al. Near-Infrared Mesoporous Silica Nanoparticles for Optical Imaging: Characterization and In Vivo Biodistribution. Adv Funct Mater 2009; 19:215 - 22; http://dx.doi.org/10.1002/adfm.200800753
   Web of Science ®Google Scholar
• Souris JS, Lee CH, Cheng SH, Chen CT, Yang CS, Ho JA, et al. Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. Biomaterials 2010; 31:5564 - 74; http://dx.doi.org/10.1016/j.biomaterials.2010.03.048; PMID: 20417962
   PubMed Web of Science ®Google Scholar
• He Q, Zhang Z, Gao F, Li Y, Shi J. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small 2011; 7:271 - 80; http://dx.doi.org/10.1002/smll.201001459; PMID: 21213393
   PubMed Web of Science ®Google Scholar
• Park JH, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew Chem Int Ed Engl 2008; 47:7284 - 8; http://dx.doi.org/10.1002/anie.200801810; PMID: 18696519
   PubMed Web of Science ®Google Scholar
• van Schooneveld MM, Vucic E, Koole R, Zhou Y, Stocks J, Cormode DP, et al. Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation. Nano Lett 2008; 8:2517 - 25; http://dx.doi.org/10.1021/nl801596a; PMID: 18624389
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009; 3:16 - 20; http://dx.doi.org/10.1021/nn900002m; PMID: 19206243
   PubMed Web of Science ®Google Scholar
• Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 2008; 14:1310-6.
   Google Scholar
• Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng 2007; 9:257 - 88; http://dx.doi.org/10.1146/annurev.bioeng.9.060906.152025; PMID: 17439359
   PubMed Web of Science ®Google Scholar
• Look M, Bandyopadhyay A, Blum JS, Fahmy TM. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Deliv Rev 2010; 62:378 - 93; http://dx.doi.org/10.1016/j.addr.2009.11.011; PMID: 19922750
   PubMed Web of Science ®Google Scholar
• Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004; 56:1649 - 59; http://dx.doi.org/10.1016/j.addr.2004.02.014; PMID: 15350294
   PubMed Web of Science ®Google Scholar
• Nabeshi H, Yoshikawa T, Matsuyama K, Nakazato Y, Arimori A, Isobe M, et al. Size-dependent cytotoxic effects of amorphous silica nanoparticles on Langerhans cells. Pharmazie 2010; 65:199 - 201; PMID: 20383940
   PubMed Web of Science ®Google Scholar
• Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000; 41:147 - 62; http://dx.doi.org/10.1016/S0169-409X(99)00062-9; PMID: 10699311
   PubMed Web of Science ®Google Scholar
• Gary-Bobo M, Hocine O, Brevet D, Maynadier M, Raehm L, Richeter S, et al. Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT. Int J Pharm 2012; 423:509 - 15; http://dx.doi.org/10.1016/j.ijpharm.2011.11.045; PMID: 22178618
   PubMed Web of Science ®Google Scholar
• Hamdy S, Haddadi A, Hung RW, Lavasanifar A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 2011; 63:943 - 55; http://dx.doi.org/10.1016/j.addr.2011.05.021; PMID: 21679733
   PubMed Web of Science ®Google Scholar
• Hamdy S, Haddadi A, Ghotbi Z, Hung RW, Lavasanifar A. Part I: targeted particles for cancer immunotherapy. Curr Drug Deliv 2011; 8:261 - 73; PMID: 21453265
   PubMed Web of Science ®Google Scholar
• Gu L, Ruff LE, Qin Z, Corr M, Hedrick SM, Sailor MJ. Multivalent porous silicon nanoparticles enhance the immune activation potency of agonistic CD40 antibody. Adv Mater 2012; 24:3981 - 7; http://dx.doi.org/10.1002/adma.201200776; PMID: 22689074
   PubMed Web of Science ®Google Scholar
• Falahati M, Saboury AA, Ma’mani L, Shafiee A, Rafieepour HA. The effect of functionalization of mesoporous silica nanoparticles on the interaction and stability of confined enzyme. Int J Biol Macromol 2012; 50:1048 - 54; http://dx.doi.org/10.1016/j.ijbiomac.2012.02.032; PMID: 22421216
   PubMed Web of Science ®Google Scholar
• Méndez J, Monteagudo A, Griebenow K. Stimulus-responsive controlled release system by covalent immobilization of an enzyme into mesoporous silica nanoparticles. Bioconjug Chem 2012; 23:698 - 704; http://dx.doi.org/10.1021/bc200301a; PMID: 22375899
   PubMed Web of Science ®Google Scholar
• Lim JS, Lee K, Choi JN, Hwang YK, Yun MY, Kim HJ, et al. Intracellular protein delivery by hollow mesoporous silica capsules with a large surface hole. Nanotechnology 2012; 23:085101; http://dx.doi.org/10.1088/0957-4484/23/8/085101; PMID: 22293239
   PubMedGoogle Scholar
• Cheng K, Blumen SR, MacPherson MB, Steinbacher JL, Mossman BT, Landry CC. Enhanced uptake of porous silica microparticles by bifunctional surface modification with a targeting antibody and a biocompatible polymer. ACS Appl Mater Interfaces 2010; 2:2489 - 95; http://dx.doi.org/10.1021/am100530t; PMID: 20707315
   PubMed Web of Science ®Google Scholar
• Lei C, Liu P, Chen B, Mao Y, Engelmann H, Shin Y, et al. Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy. J Am Chem Soc 2010; 132:6906 - 7; http://dx.doi.org/10.1021/ja102414t; PMID: 20433206
   PubMed Web of Science ®Google Scholar
• Meng H, Xue M, Xia T, Ji Z, Tarn DY, Zink JI, et al. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano 2011; 5:4131 - 44; http://dx.doi.org/10.1021/nn200809t; PMID: 21524062
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007; 2:469 - 78; http://dx.doi.org/10.1038/nnano.2007.223; PMID: 18654343
   PubMed Web of Science ®Google Scholar
• Giri S, Trewyn BG, Lin VS. Mesoporous silica nanomaterial-based biotechnological and biomedical delivery systems. Nanomedicine (Lond) 2007; 2:99 - 111; http://dx.doi.org/10.2217/17435889.2.1.99; PMID: 17716196
   PubMed Web of Science ®Google Scholar
• Chen AM, Zhang M, Wei D, Stueber D, Taratula O, Minko T, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009; 5:2673 - 7; http://dx.doi.org/10.1002/smll.200900621; PMID: 19780069
   PubMed Web of Science ®Google Scholar
• Trewyn BG, Giri S, Slowing II, Lin VS. Mesoporous silica nanoparticle based controlled release, drug delivery, and biosensor systems. Chem Commun (Camb) 2007; 3236 - 45; http://dx.doi.org/10.1039/b701744h; PMID: 17668088
   PubMed Web of Science ®Google Scholar
• Mortera R, Fiorilli S, Garrone E, Vernão E, Onida B. Pores occlusion in MCM-41 spheres immersed in SBF and the effect on ibuprofen delivery kinetics: A quantitative model. Chem Eng J 2009; 156:184 - 92; http://dx.doi.org/10.1016/j.cej.2009.10.018
   Web of Science ®Google Scholar
• Zhao Y, Sun X, Zhang G, Trewyn BG, Slowing II, Lin VS. Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects. ACS Nano 2011; 5:1366 - 75; http://dx.doi.org/10.1021/nn103077k; PMID: 21294526
   PubMed Web of Science ®Google Scholar
• Huang X, Zhuang J, Teng X, Li L, Chen D, Yan X, et al. The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species. Biomaterials 2010; 31:6142 - 53; http://dx.doi.org/10.1016/j.biomaterials.2010.04.055; PMID: 20510446
   PubMed Web of Science ®Google Scholar
• Santos HA, Bimbo LM, Herranz B, Shahbazi MA, Hirvonen J, Salonen J. Nanostructured porous silicon in preclinical imaging: Moving from bench to bedside. J Mater Res 2012; In Press http://dx.doi.org/10.1557/jmr.2012.271
   Web of Science ®Google Scholar
• Santos HA, Hirvonen . Nanostructured porous silicon materials: Potential candidates for improving drug delivery. Nanomedicine 2012; 7:1281 - 84; http://dx.doi.org/10.2217/nnm.12.106; PMID: 22994953
   PubMed Web of Science ®Google Scholar